Acadia Pharma (ACAD) Reports Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 19.41 -0.37 (1.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.78 | 52 Week High | $42.49 | |||
| Open | $19.70 | 52 Week Low | $16.64 | |||
| Day High | $19.87 | P/E | N/A | |||
| Day Low | $19.40 | EPS | $-0.42 | |||
| Volume | 1,184,491 | |||||
